ME01408B - Krystallinform beta von Ivabradine-hydrochlorid, Verfahren zu dessen Herstellung und diesen enthaltende Pharamazeutische Zusammensetzung - Google Patents

Krystallinform beta von Ivabradine-hydrochlorid, Verfahren zu dessen Herstellung und diesen enthaltende Pharamazeutische Zusammensetzung

Info

Publication number
ME01408B
ME01408B MEP-2008-551A MEP55108A ME01408B ME 01408 B ME01408 B ME 01408B ME P55108 A MEP55108 A ME P55108A ME 01408 B ME01408 B ME 01408B
Authority
ME
Montenegro
Prior art keywords
pharamcetuical
ivabradine
chlorhydrate
preparation
composition containing
Prior art date
Application number
MEP-2008-551A
Other languages
English (en)
French (fr)
Unknown language (me)
Inventor
Gerard Damien
Marie Noëlle Auguste
Stephane Horvath
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01408(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of ME01408B publication Critical patent/ME01408B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • D—TEXTILES; PAPER
    • D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H27/00—Special paper not otherwise provided for, e.g. made by multi-step processes
    • D21H27/10—Packing paper
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • B65D85/30—Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure
    • D—TEXTILES; PAPER
    • D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H21/00—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties
    • D21H21/14—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties characterised by function or properties in or on the paper
    • D21H21/16—Sizing or water-repelling agents
    • D—TEXTILES; PAPER
    • D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H27/00—Special paper not otherwise provided for, e.g. made by multi-step processes
    • D21H27/30—Multi-ply
    • D21H27/40—Multi-ply at least one of the sheets being non-planar, e.g. crêped
MEP-2008-551A 2005-02-28 2006-02-28 Krystallinform beta von Ivabradine-hydrochlorid, Verfahren zu dessen Herstellung und diesen enthaltende Pharamazeutische Zusammensetzung ME01408B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501985A FR2882553B1 (fr) 2005-02-28 2005-02-28 Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
EP06290326A EP1695965B9 (de) 2005-02-28 2006-02-28 Krystallinform beta von Ivabradine-hydrochlorid, Verfahren zu dessen Herstellung und diesen enthaltende Pharamazeutische Zusammensetzung

Publications (1)

Publication Number Publication Date
ME01408B true ME01408B (de) 2010-06-30

Family

ID=34954954

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-551A ME01408B (de) 2005-02-28 2006-02-28 Krystallinform beta von Ivabradine-hydrochlorid, Verfahren zu dessen Herstellung und diesen enthaltende Pharamazeutische Zusammensetzung

Country Status (43)

Country Link
US (3) US7361649B2 (de)
EP (1) EP1695965B9 (de)
JP (1) JP4625776B2 (de)
KR (1) KR100827502B1 (de)
CN (1) CN1827600B (de)
AP (1) AP1907A (de)
AR (1) AR053147A1 (de)
AT (1) ATE407926T1 (de)
BR (1) BRPI0600623A (de)
CA (1) CA2537414C (de)
CO (1) CO5770096A1 (de)
CR (1) CR8248A (de)
CU (1) CU23614B7 (de)
CY (1) CY1109072T1 (de)
DE (1) DE602006002624D1 (de)
DK (1) DK1695965T3 (de)
EA (1) EA008464B1 (de)
EC (2) ECSP066375A (de)
ES (1) ES2313581T3 (de)
FR (1) FR2882553B1 (de)
GE (1) GEP20084465B (de)
GT (1) GT200600084A (de)
HK (1) HK1096387A1 (de)
HR (1) HRP20080520T3 (de)
IL (1) IL173957A0 (de)
JO (1) JO2548B1 (de)
MA (1) MA28131A1 (de)
ME (1) ME01408B (de)
MY (1) MY158128A (de)
NO (1) NO338370B1 (de)
NZ (1) NZ545576A (de)
PE (1) PE20061009A1 (de)
PL (1) PL1695965T3 (de)
PT (1) PT1695965E (de)
RS (1) RS50661B (de)
SA (1) SA06270038B1 (de)
SG (1) SG125228A1 (de)
SI (1) SI1695965T1 (de)
TW (1) TWI314144B (de)
UA (1) UA80904C2 (de)
UY (1) UY29405A1 (de)
WO (1) WO2006092493A1 (de)
ZA (1) ZA200601762B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
ES2381771T3 (es) 2006-11-30 2012-05-31 Cadila Healthcare Limited Procedimiento para la preparación de hidrocloruro de ivabradina
FR2911279B1 (fr) * 2007-01-11 2009-03-06 Servier Lab Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
KR101478855B1 (ko) 2007-05-30 2015-01-02 인드-스위프트 래버러토리즈 리미티드 이바브라딘 히드로클로라이드 및 그의 다형태의 제조방법
FR2938194B1 (fr) * 2008-11-07 2012-08-31 Servier Lab Utilisation de l'ivabradine comme agent de diagnostic dans la methode d'angiographie coronaire par tomodensitometrie multicoupe
CN102264689B (zh) 2008-12-22 2014-12-31 新梅斯托克尔卡公司 制备伊伐布雷定的方法
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
SI23290A (sl) 2010-02-12 2011-08-31 Krka D.D., Novo Mesto Nove oblike ivabradin hidroklorida
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其ｉ型結晶的製備方法
CA2800442C (en) 2010-06-14 2018-05-22 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition with modified release
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
CN102304088B (zh) * 2011-07-07 2013-06-19 石药集团欧意药业有限公司 一种伊伐布雷定化合物、制备方法及其药物组合物
WO2013017582A1 (en) 2011-08-02 2013-02-07 Sandoz Ag Acetone solvate of ivabradine hydrochloride
EP2589594A1 (de) 2011-11-04 2013-05-08 Urquima S.A. Ivabradin-Hydrochloridform IV
EP2773621B1 (de) 2011-11-04 2015-12-30 Synthon BV Verfahren zur herstellung einer kristallinen delta-form von ivabradinhydrochlorid
US9120755B2 (en) 2011-11-14 2015-09-01 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
WO2014080259A1 (en) * 2012-11-21 2014-05-30 Enaltec Labs Pvt. Ltd. Novel polymorphic forms of alcaftadine
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
HUE047705T2 (hu) 2013-03-19 2020-05-28 Chemo Res S L Ivabradin-hidroklorid új polimorfja és eljárás elõállítására
CZ2013767A3 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
WO2015001133A1 (en) 2013-12-12 2015-01-08 Synthon B.V. Pharmaceutical composition comprising amorphous ivabradine
ES2717715T3 (es) 2014-02-14 2019-06-24 Synthon Bv Composición farmacéutica que comprende polimorfo IV de clorhidrato de ivabradina
CZ305436B6 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2016102423A1 (en) 2014-12-22 2016-06-30 Ratiopharm Gmbh Composition comprising ivabradine in a dissolved form
GR1008821B (el) 2015-06-11 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει υδροχλωρικη ιβαμπραδινη και μεθοδος παρασκευης αυτου
CN107056706B (zh) * 2015-12-21 2020-05-05 江苏恒瑞医药股份有限公司 一种用于制备盐酸伊伐布雷定α晶型的方法
US11273162B2 (en) * 2016-04-01 2022-03-15 Mississippi State University Compositions and methods targeting HCN channels for breathing therapeutics
EP3366282A1 (de) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Feste orale pharmazeutische zusammensetzungen von ivabradin
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
WO2020092288A1 (en) 2018-10-30 2020-05-07 Amgen Inc. Process of making ivabradine hydrochloride drug product
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US4490369A (en) * 1981-05-19 1984-12-25 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Benzazepine derivatives, their pharmaceutical compositions and method of use
EP0547151B1 (de) 1990-08-29 2002-11-20 Humanetics Corporation Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2818552B1 (fr) 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
FR2834896B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'ivabradine
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
AU2006200856A1 (en) 2010-01-28
US7361649B2 (en) 2008-04-22
MA28131A1 (fr) 2006-09-01
CA2537414C (fr) 2010-02-16
CY1109072T1 (el) 2014-07-02
EP1695965B9 (de) 2009-03-04
ECSP066375A (es) 2006-11-16
MY158128A (en) 2016-08-30
CU20060039A7 (es) 2008-06-30
CN1827600B (zh) 2010-08-11
US7879842B2 (en) 2011-02-01
FR2882553B1 (fr) 2007-05-04
SG125228A1 (en) 2006-09-29
HK1096387A1 (en) 2007-06-01
EA008464B1 (ru) 2007-06-29
EP1695965A1 (de) 2006-08-30
CA2537414A1 (fr) 2006-08-28
NO20060946L (no) 2006-08-29
PL1695965T3 (pl) 2009-01-30
CU23614B7 (es) 2011-01-27
ECSP066373A (es) 2006-10-17
ES2313581T3 (es) 2009-03-01
AP1907A (en) 2008-10-23
US20100041640A1 (en) 2010-02-18
PE20061009A1 (es) 2006-11-18
WO2006092493A1 (fr) 2006-09-08
EA200600322A1 (ru) 2006-08-25
KR20060095501A (ko) 2006-08-31
CN1827600A (zh) 2006-09-06
FR2882553A1 (fr) 2006-09-01
AP2006003519A0 (en) 2006-02-28
IL173957A0 (en) 2006-07-05
RS50661B (sr) 2010-06-30
AR053147A1 (es) 2007-04-25
SA06270038B1 (ar) 2010-03-29
US20080161285A1 (en) 2008-07-03
CO5770096A1 (es) 2007-06-29
BRPI0600623A (pt) 2006-10-24
UY29405A1 (es) 2006-07-31
EP1695965B1 (de) 2008-09-10
GT200600084A (es) 2006-11-22
NZ545576A (en) 2007-01-26
ZA200601762B (en) 2007-04-25
JO2548B1 (en) 2010-09-05
DE602006002624D1 (de) 2008-10-23
JP2006241154A (ja) 2006-09-14
GEP20084465B (en) 2008-08-25
DK1695965T3 (da) 2008-12-15
NO338370B1 (no) 2016-08-15
HRP20080520T3 (en) 2009-01-31
KR100827502B1 (ko) 2008-05-06
TWI314144B (en) 2009-09-01
US20060194962A1 (en) 2006-08-31
SI1695965T1 (sl) 2009-02-28
JP4625776B2 (ja) 2011-02-02
CR8248A (es) 2008-10-06
UA80904C2 (en) 2007-11-12
PT1695965E (pt) 2008-10-08
ATE407926T1 (de) 2008-09-15
TW200640873A (en) 2006-12-01

Similar Documents

Publication Publication Date Title
SI1695965T1 (sl) Beta kristalna oblika ivabradin-hidroklorida in farmacevtski sestavki, ki jo vsebujejo
ME02747B (de) Krystallinform gamma von Ivabradine-hydrochlorid, Verfahren zu dessen Herstellung und diesen enthaltende Pharamazeutische Zusammensetzung
PL1695709T3 (pl) Postać krystaliczna gamma-d chlorowodorku iwabradyny, sposób jej wytwarzania i kompozycje farmaceutyczne zawierające tę postać
ME02026B (de) Neue kristalline Form V von Agometalin, Verfahren zur deren Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen
PT2210872T (pt) Nova forma cristalina iii de agomelatina, processo para a sua preparação e composições farmacêuticas que a contêm
PL1695710T3 (pl) Postać krystaliczna beta-d chlorowodorku iwabradyny, sposób jej otrzymywania i zawierające je kompozycje farmaceutyczne
AP2185A (en) de, a process for its preparation and pharmaceuticDelta d crystalline form of ivabradine hydrochlorial compositions containing it.
IL178544A (en) Crystalline form - δ of ivabradine hydrochloride, process for preparation and pharmaceutical preparations containing it
ZA200606455B (en) Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
HRP20130656T1 (hr) Derivati benzonitrila supstituirani glukopiranozilom, farmaceutski sastavi koji sadrže takve spojeve, njihova uporaba i postupak njihove proizvodnje
ZA200703277B (en) Novel pyrimidine compounds, process for their preparation and compositions containing them
IL193385A0 (en) Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
ZA200804802B (en) Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
HK1126190A1 (en) Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them
IL203433A (en) Process for Preparing Pharmaceutical and Solid Release Controlled Compositions Containing Oxacarbazapine
IL189177A0 (en) Process for producing carcosporamide and pharmaceutical compositions containing cercosporamide